PTCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PTC Therapeutics Inc (PTCT) is not a strong buy at the moment for a beginner investor with a long-term strategy. The recent withdrawal of the Translarna NDA submission has significantly impacted market confidence and introduces uncertainty regarding the company's drug pipeline. While hedge funds are buying and analysts have raised price targets, the negative news and weak financial performance outweigh the positive catalysts. A 'hold' recommendation is more prudent given the current scenario.
The technical indicators suggest a bearish trend. The MACD is negative and expanding downward, RSI is neutral but leaning towards oversold territory, and the stock is trading near its key support level of 70.589. Moving averages are converging, indicating indecision in the market.
Hedge funds are significantly increasing their positions, with a 3181.08% increase in buying over the last quarter.
Analysts have raised price targets, with Barclays highlighting a $2B sales opportunity in phenylketonuria that is underappreciated.
The withdrawal of the Translarna NDA submission due to FDA feedback has caused a loss of market confidence and a ~5% drop in after-hours trading.
The company's competitiveness in the biopharmaceutical market is diminished, and its drug development efforts face significant challenges.
Financial performance in Q3 2025 showed a sharp decline in net income (-114.90% YoY) and EPS (-112.95% YoY).
In Q3 2025, revenue increased by 7.23% YoY to $211 million, but net income dropped by -114.90% YoY to $15.9 million. EPS also declined by -112.95% YoY to 0.18, and gross margin fell by 4.29% YoY to 88.95%. These figures indicate weak profitability and declining margins.
Analysts have a mixed but generally positive outlook. Barclays upgraded the stock to Overweight with a price target of $119, citing a $2B sales opportunity in phenylketonuria. BofA raised its price target to $97, maintaining a Buy rating. However, TD Cowen raised its target to $75 but kept a Hold rating, reflecting cautious optimism.
